Two Decades of Advances in Colorectal Cancer Prevention and Treatment: From Aspirin to Precision Oncology
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 37
Special Issue Editors
2. South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX 78504, USA
Interests: cancer progression; metastasis; lncRNA; transcription regulation; drug resistance; anoikis; CRC; HCC
Special Issues, Collections and Topics in MDPI journals
2. Michigan Public Health Institute, Okemos, MI 48842, USA
Interests: colon cancer; cancer biomarkers; resistance; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, ‘Two Decades of Advances in Colorectal Cancer Prevention and Treatment: From Aspirin to Precision Oncology’, highlights the remarkable progress made in colorectal cancer research, prevention, and clinical management over the last twenty years. As our understanding of the disease has deepened, innovative approaches, from chemoprevention strategies to precision-guided therapies, have transformed patient care and outcomes.
This Special Issue seeks to present a curated collection of original research, comprehensive reviews, and expert insights that explore the evolution of colorectal cancer treatment, the integration of precision medicine, and the development of novel strategies to address ongoing clinical challenges.
The scope of the Special Issue includes, but is not limited to, the following:
- Molecular mechanisms of colorectal carcinogenesis: Insights into key signaling pathways and genetic alterations driving disease progression.
- Chemoprevention: Efficacy and mechanisms of agents such as aspirin, NSAIDs, and dietary compounds in reducing colorectal cancer risk.
- Innovations in screening and early detection: Advances in molecular diagnostics, imaging modalities, and non-invasive tools, including liquid biopsy (e.g., ctDNA, microRNAs).
- Targeted therapies: Development and clinical application of EGFR inhibitors, VEGF inhibitors, BRAF inhibitors, and rational combination therapies.
- Immunotherapy approaches: Progress in checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and the immunogenomic landscape of colorectal tumors.
- Precision oncology: Application of genomic, transcriptomic, epigenomic, and proteomic data to tailor treatment strategies to individual patients.
- Emerging therapeutics: Investigating novel drug targets, biomarker-driven combination regimens, and adaptive treatment approaches.
- Therapy resistance: Understanding and overcoming resistance to chemotherapy, targeted therapies, and immunotherapies.
We invite contributions that capture the significant strides made in colorectal cancer care and explore future opportunities for innovation in precision oncology.
Dr. Manish Tripathi
Dr. Puneet Vij
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- biomarkers
- colorectal cancer
- targeted therapies
- molecular pathways
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
